Core Viewpoint - Monopar Therapeutics Inc. reported a productive year in 2025, highlighted by advancements in its ALXN1840 program for Wilson disease, a strengthened balance sheet, and leadership team enhancements as it prepares for a potential drug launch [2] Recent Program Developments - ALXN1840 is set for a New Drug Application (NDA) submission in mid-2026, targeting Wilson disease, a rare genetic disorder that leads to copper accumulation in organs [3][4] - The drug operates through a novel mechanism as an albumin tripartite complex (ATC) activator, distinguishing it from existing therapies [3] - The MNPR-101 platform includes radiopharmaceutical programs targeting aggressive cancers, with ongoing Phase 1 clinical activities for MNPR-101-Zr and MNPR-101-Lu [4][6] Financial Highlights - Monopar's cash, cash equivalents, and short-term investments totaled $140.4 million as of December 31, 2025, expected to support operations through at least December 31, 2027 [8] - The net loss for Q4 2025 was $5.2 million ($0.61 per share), a decrease from $10.9 million ($2.23 per share) in Q4 2024 [9] - For the full year 2025, the net loss was $13.7 million ($1.85 per share), down from $15.6 million ($4.11 per share) in 2024 [9] Research and Development (R&D) Expenses - R&D expenses for Q4 2025 were $3.9 million, significantly lower than $9.9 million in Q4 2024, primarily due to the absence of one-time expenses from 2024 [10] - For the full year, R&D expenses were $9.9 million, down from $13.0 million in 2024, reflecting a shift in focus following the in-licensing of ALXN1840 [11] General and Administrative (G&A) Expenses - G&A expenses for Q4 2025 increased to $2.2 million from $1.2 million in Q4 2024, driven by higher personnel costs and legal fees [12] - For the year, G&A expenses rose to $6.8 million from $3.2 million in 2024, attributed to similar factors as the quarterly increase [13]

Core Insights - Monopar Therapeutics Inc. has appointed Susan Rodriguez as Chief Commercial and Strategy Officer to lead the company's commercial strategy and infrastructure as it prepares for the New Drug Application submission for ALXN1840, a therapy for Wilson disease, in the first half of 2026 [1][2] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with a late-stage investigational therapy ALXN1840 for Wilson disease and several radiopharmaceutical programs [3] Leadership Appointment - Susan Rodriguez brings over 30 years of biopharmaceutical leadership experience, having previously served as Chief Operating Officer at Avadel Pharmaceuticals, where she contributed to a $2 billion acquisition [2] - Rodriguez has a proven track record in launching rare disease therapies and building commercial teams, which will be crucial for Monopar as it advances ALXN1840 toward approval [2] Product Development - ALXN1840 is positioned as the first major advancement in Wilson disease treatment in decades, with the company aiming to ensure broad patient access and maximize the therapy's impact [2]

Core Viewpoint - Monopar Therapeutics Inc. reported its third quarter 2025 financial results, highlighting advancements in its drug candidates and recent financing activities, indicating a strong position for future growth and regulatory submissions [1]. Recent Developments - ALXN1840 for Wilson Disease: New data presented at the 150th American Neurological Association Annual Meeting demonstrated long-term neurological efficacy and safety of ALXN1840, emphasizing its potential to positively impact both neurological and hepatic manifestations of Wilson disease [2][3]. - MNPR-101 for Radiopharmaceutical Use: The FDA cleared the IND application for MNPR-101-Lu, which aims to treat advanced or metastatic solid tumors, utilizing proprietary linker technology to enhance therapeutic efficacy [5]. Recent Financing Capital Raise and Share Repurchase - On September 23, 2025, Monopar priced a public offering of 1,034,433 shares at $67.67 per share, raising approximately $126.9 million in net proceeds [6]. - Following the offering, the company repurchased 550,229 shares from Tactic Pharma for $35 million, resulting in net proceeds of approximately $91.9 million after the share repurchase [7]. Financial Results for the Third Quarter Ended September 30, 2025 - Cash, cash equivalents, and investments totaled $143.7 million, sufficient to support operations through at least December 31, 2027, while advancing multiple clinical trials and R&D projects [9]. - The net loss for Q3 2025 was $3.4 million, or $0.48 per share, compared to a net loss of $1.3 million, or $0.37 per share, in Q3 2024 [10]. - R&D expenses increased to $2.59 million, primarily due to higher manufacturing activities and personnel costs [11]. - G&A expenses rose to $1.50 million, driven by increased board compensation and personnel expenses [12]. - Interest income increased by $556,129, attributed to higher bank balances and interest earned on U.S. Treasury securities [13]. Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with key programs including ALXN1840 for Wilson disease and various radiopharmaceutical candidates [14].

Core Insights - Monopar Therapeutics Inc. has been identified as a promising investment opportunity, with Raymond James raising its price target from $80 to $142 while maintaining a Strong Buy rating [1][3] Financial Performance - In Q2 2025, Monopar reported a net loss of $2.5 million ($0.35 per share), an increase from a net loss of $1.7 million ($0.49 per share) in Q2 2024 [2] - The company has cash, cash equivalents, and investments totaling $53.3 million, which is expected to support operations through December 31, 2026 [2] Development Pipeline - The increased price target reflects confidence in the company's ability to execute its anticipated timeline, including filing an NDA for ALXN1840, completing its Phase 1 imaging/dosimetry trial for MNPR-101-Zr, continuing its Phase 1a therapeutic trial for MNPR-101-Lu, and advancing the preclinical MNPR-101-Ac program into the clinic [3]

Core Insights - Monopar Therapeutics Inc. announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the AASLD – The Liver Meeting 2025, scheduled for November 7-11, 2025 in Washington, D.C. [1] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs [3] - The company is also working on Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for treating advanced cancers [3] Presentation Details - The abstract for the oral presentation is available on the conference website, with materials to be accessible on Monopar's website on November 9, 2025 [2] - The presentation will take place on November 9, 2025, from 9:00-9:15 am EST, featuring the presenting author Aftab Ala, MBBS, M.D., FRCP, Ph.D. [5]

Market Outlook - Ryan Detrick, chief market strategist at Carson Group, anticipates a strong end-of-year rally despite historically weak periods in late September and early October [1] - The market has experienced five consecutive months of gains, which historically leads to an average decline in October, suggesting a potential break for investors [1] - Q4 typically shows a median return of nearly 6% when the market has been up for five months prior, indicating bullish sentiment [1] Investment Strategy - Detrick expressed a desire for a mild correction of 4-6%, viewing it as a healthy market adjustment [2] - Current market indicators include low put-to-call ratios and a significant inflow of $58 billion into US equity funds, the highest this year [2] - Anticipated volatility around Jewish holidays and early October may present buying opportunities, driven by strong earnings and consumer performance [2] Company Highlights Monopar Therapeutics Inc. (NASDAQ:MNPR) - Achieved a 3-month performance of 100.82% as of October 10, with an average upside potential of 20.70% [7][8] - Raymond James raised the price target from $80 to $142, maintaining a Strong Buy rating, indicating confidence in the company's future performance [8] - Reported a net loss of $2.5 million for Q2 2025, an increase from a net loss of $1.7 million in Q2 2024, with cash reserves of $53.3 million to support operations through December 2026 [9] Mesoblast Limited (NASDAQ:MESO) - Recorded a 3-month performance of 64.01% as of October 10, with an average upside potential of 56.16% [11] - The company received a permanent J-Code for its product Ryoncil, enhancing billing and reimbursement pathways, which is a significant commercial milestone [12] - Ryoncil is the first FDA-approved mesenchymal stromal cell product for pediatric patients with steroid-refractory acute graft-versus-host disease, expanding its market potential [13][14]

Company Highlights - Cidara Therapeutics Inc. (CDTX) reached a 52-week high of $87.19 as it advances its development plan for CD388, a non-vaccine preventive treatment for seasonal influenza, with enrollment in a Phase 3 study expected to start by September 2025 targeting 6,000 participants [1] - Maze Therapeutics Inc. (MAZE) saw its stock rise to a 52-week high of $27.09 following positive Phase 1 clinical results for MZE782, an oral therapy for Phenylketonuria and chronic kidney disease, with plans to enter Phase 2 studies in 2026 [3][4] - Medpace Holdings Inc. (MEDP) is set to report Q3 2025 financial results on October 22, 2025, and has raised its full-year guidance twice, indicating strong operational momentum, with the stock hitting a 52-week high of $506.55 [5][6] - Monopar Therapeutics Inc. (MNPR) rebounded from potential Nasdaq delisting to a 52-week high of $73.75, planning to seek approval for ALXN1840 for Wilson disease in early 2026, supported by long-term clinical data [7][8] - Prenetics Global Limited (PRE) projects 2025 revenue between $85 million and $100 million, a significant increase from $30.6 million in 2024, with its new wellness brand IM8 Health on track for $100 million in annual recurring revenue [9][10] - Protagonist Therapeutics Inc. (PTGX) is nearing a major milestone with Icotrokinra for psoriasis, having submitted a regulatory application to the FDA and EMA in July 2025, with the stock reaching a 52-week high of $66.70 [11][12] - uniQure N.V. (QURE) announced positive results from its Phase I/II study of AMT-130 for Huntington's disease, planning to submit a Biologics License Application in Q1 2026, with the stock soaring over 200% to a 52-week high of $51.21 [13][14] - Rezolute Inc. (RZLT) surged to a 52-week high of $9.02 ahead of topline results from its pivotal Phase III trial for hypoglycemia treatment, expected in December [15][16] - United Therapeutics Corp. (UTHR) reached a 52-week high of $442.01 as anticipation builds for data from the TETON-2 study of nebulized Tyvaso in idiopathic pulmonary fibrosis, with positive results reported earlier [17][18]

Core Viewpoint - Monopar Therapeutics Inc. has announced a registered offering of common stock and pre-funded warrants, aiming to raise approximately $100 million for general corporate purposes, including research and development [1][2][3]. Group 1: Offering Details - The offering consists of 1,034,433 shares of common stock priced at $67.67 per share and pre-funded warrants to purchase 960,542 shares at $67.669 each [1]. - The gross proceeds from the offering, net of anticipated stock repurchase, are expected to be around $100 million before underwriting discounts and expenses [2]. - The offering is anticipated to close on or about September 25, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - Monopar plans to allocate up to $35 million of the proceeds to repurchase shares from Tactic Pharma, LLC at a price of $63.6098 per share, which is equivalent to the offering price for investors [3]. Group 3: Management and Registration - Morgan Stanley, Leerink Partners, and Barclays are serving as lead book-running managers for the offering [4]. - The securities are being offered under a "shelf" registration statement filed with the SEC, with a prospectus supplement to be made available [5]. Group 4: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments, including late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs for advanced cancers [7].

Core Insights - Monopar Therapeutics Inc. announced the publication of a peer-reviewed Letter to the Editor in the Journal of Hepatology, discussing the effects of ALXN1840 on copper balance in patients with Wilson disease [1][2] Group 1: Study Findings - The earlier conclusion from the Phase 2 ALXN1840-WD-204 study indicated that ALXN1840 did not promote copper excretion due to methodological limitations in the copper balance equation [2] - The new analysis shows that ALXN1840 statistically significantly improved copper balance, increasing copper excretion over the study duration [2] - Key findings include: - For the 15 mg/day treatment period, the mean daily difference in copper balance was -0.367 mg (p=0.005) - For the overall treatment period, the mean daily difference was -0.289 mg (p=0.023) - The cumulative mean change from baseline was -6.08 mg (95% CI: -10.18 mg to -1.98 mg) [5] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including late-stage ALXN1840 for Wilson disease [8] - The company also has radiopharmaceutical programs in various stages of development for imaging and treating advanced cancers [8]

Core Insights - Monopar Therapeutics Inc. announced the publication of a peer-reviewed Letter to the Editor in the Journal of Hepatology, discussing the effects of ALXN1840 on copper balance in patients with Wilson disease [1][2] Group 1: Study Findings - The earlier conclusion from the Phase 2 ALXN1840-WD-204 study indicated that ALXN1840 did not promote copper excretion due to methodological limitations in the copper balance equation [2] - By comparing pre- and post-treatment data, the analysis showed that ALXN1840 statistically significantly improved copper balance, leading to increased copper excretion [2] - Key findings from the study include: - For the 15 mg/day treatment period, the mean daily difference in copper balance was -0.367 mg (p=0.005) - For the overall treatment period, including dose changes, the mean daily difference was -0.289 mg (p=0.023) - The cumulative mean change from baseline was -6.08 mg (95% CI: -10.18 mg to -1.98 mg) [5] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs [8]